Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

  • End date
    Feb 29, 2024
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 27 December 2021


This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

Condition Diabetic Peripheral Neuropathic Pain
Treatment Placebo, LY3556050
Clinical Study IdentifierNCT04707157
SponsorEli Lilly and Company
Last Modified on27 December 2021


Yes No Not Sure

Inclusion Criteria

Have a visual analog scale (VAS) pain value ≥40 and <95 during screening
Have a history of daily pain for at least 12 weeks based on participant report or medical history
Have a body mass index <40 kilograms per meter squared (kg/m²) (inclusive)
Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation
Are willing to discontinue all pain medications taken for chronic pain conditions for the duration of the study
Have daily symmetrical foot pain secondary to peripheral neuropathy present for at least 6 months and as diagnosed through use of the Michigan Neuropathy Screening Instrument Part B ≥3 (©University of Michigan)
Have a history and current diagnosis of type 1 or type 2 diabetes mellitus
Have stable glycemic control as indicated by a glycated hemoglobin ≤11 at time of screening
Are men, or women able to abide by reproductive and contraceptive requirements

Exclusion Criteria

Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
Have surgery planned during the study for any reason, related or not to the disease state under evaluation
Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation
Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision
Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide
Have a positive human immunodeficiency virus (HIV) test result at screening
Have an intolerance to acetaminophen or paracetamol or any of its excipients
Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening
Have a current drug-induced neuropathy, for example, due to some types of chemotherapy, or other types of peripheral neuropathy
Have known hereditary motor, sensory or autonomic neuropathies
Have a history within 2 years prior to screening or current evidence of syncope, presyncope, uncontrolled vertigo, or postural dizziness, judged to be clinically significant by the investigator
Have clinically significant active thyroid disease, including Hashimoto's thyroiditis
Are taking metformin therapy. Metformin Exception Limited dosages of metformin are allowed in this study. Additional exclusion criteria for participants taking metformin
Have a history or presence of lactic acidosis
Are pregnant or breastfeeding
Have a history or presence of severe hepatic disease including cirrhosis
Have fibromyalgia
Have uncontrolled or unstable congestive heart failure
Are taking carbonic anhydrase inhibitors if also taking metformin
Have had a change in metformin therapy in the last 12 weeks
Have not maintained a stable dose of glucose-lowering agents other than metformin before randomization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note